[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 449
Citations 0
Health Agencies Update
March 28, 2012

HIV, Hepatitis Drug Interactions

JAMA. 2012;307(12):1243. doi:10.1001/jama.2012.332

Certain combinations of medications used to treat HIV and hepatitis C infection may lead to lower blood levels of these drugs, potentially reducing their efficacy, according to a US Food and Drug Administration (FDA) alert.

Citing evidence from a pharmacokinetic study, the FDA warned that patients taking the hepatitis C–targeted protease inhibitor boceprevir along with any of the ritonavir-boosted HIV-targeting protease inhibitors atazanavir, darunavir, or lopinavir may have lower blood levels of 1 or both drugs. The label of boceprevir will be updated to indicate this potential interaction, and the drug's manufacturer has sent letters to warn physicians.

First Page Preview View Large
First page PDF preview
First page PDF preview
×